

Application Serial No. 10/801,956

PATENT
89212.0017

Amendment to the specification:

Please replace the paragraph beginning at page 4, line 11 with the following rewritten paragraph:

The invention is also based on the unexpected discovery that DNA markers in the *12q22-23* region are useful prognostic predictors for disease outcomes and responses to therapies. Therefore, the invention provides a method of determining the probability of survival, comprising providing a sample from a subject suffering from a metastatic cancer and detecting one or more DNA markers in the *12q22-23* region in the sample, wherein LOH of the markers indicates a low probability of survival. The sample may be, e.g., a tumor sample, -a serum sample, or -a plasma sample. The cancer may be melanoma, e.g., a stage III melanoma such as an RLM (regional lymph node metastasis) melanoma or an ITM (in-transit metastasis) melanoma, or a stage IV melanoma. Other examples of cancers include colon cancer, breast cancer, and brain cancer.